Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT ID: NCT01874769

Last Updated: 2025-01-29

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 30 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2017-08-31

Brief Summary

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is one of the most severe rare inherited skin disorders affecting children and adults. Current medical care protocols for RDEB patients are limited to palliative procedures to treat blistering and erosive lesions, wounds, and severe local and systemic complications such as fusion and contracture of the digits, skin cancer, esophageal stricture, severe anemia, infections, malnutrition and growth retardation. However, current medical treatments still cannot prevent the recurrence of the lesions arising from defective expression of type VII collagen (COL7A1), the main constituent of anchoring fibrils which form essential structures for dermal-epidermal adherence.

The purpose of this study is to investigate the capacity of keratinocytes and fibroblasts to repair skin wounds in patients suffering from Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Detailed Description

In the perspective of future therapeutic interventions, which could involve protein, cellular and/or gene therapy, it is essential to investigate RDEB patients with regards to their immune tolerance to type VII collagen and their capacity of their cells for tissue reconstruction.

Conditions

Recessive Dystrophic Epidermolysis Bullosa

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Blood collection and skin biopsies

Blood collection

Intervention Type: OTHER

• 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.
• 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen
• 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria.

Skin biopsies

Intervention Type: OTHER

• A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.
• During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients

Interventions

Blood collection

• 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.
• 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen
• 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria.

Intervention Type: OTHER

Skin biopsies

• A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.
• During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Confirmed molecular diagnosis of recessive dystrophic epidermolysis bullosa, established for both alleles;
• Non severe generalized clinical form of RDEB;
• Presence of type VII collagen on skin biopsy and/or western-blot analysis detected with a set of specific antibodies;
• Presence of intact skin areas without blisters, infection or erosion;
• Absence of hospitalization related to EB condition;
• Patients and their parents when applicable should be able and willing to return for follow up;
• Patients should be able and willing to give signed informed consent. For patients who are minor, informed consent will be signed by a legally authorized representative, as well as an assent form by the minor patient.
• Ability to undergo local anesthesia.

Exclusion Criteria

• Severity of disease and presence of ill-prognostic features:

1. Premature termination codon in the noncollagenous (NC1) domain of COL7A1 on both alleles;

2. Absence of detectable type VII collagen expression on skin biopsy and Western blot analysis from cultured cells;

• Underlying conditions, diseases or active infections likely to increase the risk of complications or to interfere with the biological investigations:

1. History of current or previous skin cancer (Squamous cell carcinoma or other malignant skin cancer);

2. Current infectious diseases, including systemic infections and known positive HIV serology (Kaposi's sarcoma), hepatitis B and C;

3. History of current psychological or psychiatric disease;

4. Absence of an adequate familial and social support;

5. History of current or previous organ diabetes mellitus;

6. Non corrected severe anemia (Hemoglobin level: < 8 g/ml);

7. Non corrected iron deficiency;

8. History of significant allergy to an anaesthetic procedure

9. Patient currently receiving anticoagulant or anti-aggregation treatment;

10. Participation in another clinical trial or therapy protocol for RDEB at the time of study inclusion

11. Positive pregnancy urinary test or lactating women

• Not affiliated to the national social security/health service beneficiary and families with beneficiary children.

• Minimum Eligible Age: 7 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alain Hovnanian, Prof

Role: PRINCIPAL_INVESTIGATOR

National Institut of health and medical research

Locations

Service de dermatologie Necker Hospital for sick children

Paris, , France

Inserm U781 Service de Génétique Necker Hospital for sick children

Paris, , France

Guy's and ST Thomas NHS Foundation trust/Guy's Hospital

London, , United Kingdom

Countries

France; United Kingdom

Other Identifiers

2012-A01051-42

Identifier Type: REGISTRY

Identifier Source: secondary_id

C12-22

Identifier Type: -

Identifier Source: org_study_id